

MTN 036 - Pharmacokinetics and safety study of extended duration Dapivirine vaginal rings
Report Generation Date: December 2, 2025
Visit Cutoff Date: December 1, 2025¹
Retention by Visit and Site

	All Sites	Birmingham, AL	San Francisco, CA
Participants Enrolled	49	25	24
Day 1 Visit			
Expected ²	49	25	24
Completed ³	48 (98%)	24 (96%)	24 (100%)
Not Completed	1 (2%)	1 (4%)	0 (0%)
Missed	1 (2%)	1 (4%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
Day 2 Visit			
Expected ²	49	25	24
Completed ³	49 (100%)	25 (100%)	24 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
Day 3 Visit			
Expected ²	49	25	24
Completed ³	48 (98%)	25 (100%)	23 (96%)
Not Completed	1 (2%)	0 (0%)	1 (4%)
Missed	1 (2%)	0 (0%)	1 (4%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 036 - Pharmacokinetics and safety study of extended duration Dapivirine vaginal rings

Report Generation Date: December 2, 2025

Visit Cutoff Date: December 1, 2025¹

Retention by Visit and Site

	All Sites	Birmingham, Al	San Francisco, CA
Day 7 / Week 1 Visit			
Expected ²	49	25	24
Completed ³	48 (98%)	25 (100%)	23 (96%)
Not Completed	1 (2%)	0 (0%)	1 (4%)
Missed	1 (2%)	0 (0%)	1 (4%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
Day 14 / Week 2 Visit			
Expected ²	49	25	24
Completed ³	47 (96%)	24 (96%)	23 (96%)
Not Completed	2 (4%)	1 (4%)	1 (4%)
Missed	1 (2%)	1 (4%)	0 (0%)
Terminated Early	1 (2%)	0 (0%)	1 (4%)
Not Expected	0	0	0
Day 28 / Week 4 Visit			
Expected ²	49	25	24
Completed ³	48 (98%)	25 (100%)	23 (96%)
Not Completed	1 (2%)	0 (0%)	1 (4%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	1 (2%)	0 (0%)	1 (4%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 036 - Pharmacokinetics and safety study of extended duration Dapivirine vaginal rings

Report Generation Date: December 2, 2025

Visit Cutoff Date: December 1, 2025¹

Retention by Visit and Site

	All Sites	Birmingham, Al	San Francisco, CA
Day 56 / Week 8 Visit			
Expected ²	49	25	24
Completed ³	46 (94%)	24 (96%)	22 (92%)
Not Completed	3 (6%)	1 (4%)	2 (8%)
Missed	1 (2%)	1 (4%)	0 (0%)
Terminated Early	2 (4%)	0 (0%)	2 (8%)
Not Expected	0	0	0
Day 91 / Week 13 Product End Use Visit (PUEV)			
Expected ²	49	25	24
Completed ³	43 (88%)	21 (84%)	22 (92%)
Not Completed	6 (12%)	4 (16%)	2 (8%)
Missed	4 (8%)	4 (16%)	0 (0%)
Terminated Early	2 (4%)	0 (0%)	2 (8%)
Not Expected	0	0	0
Day 92/93/94 Final Contact			
Expected ²	49	25	24
Completed ³	44 (90%)	22 (88%)	22 (92%)
Not Completed	5 (10%)	3 (12%)	2 (8%)
Missed	3 (6%)	3 (12%)	0 (0%)
Terminated Early	2 (4%)	0 (0%)	2 (8%)
Not Expected	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.